Sign In
5 Sep 2008 08:54
4 September 2008Cyprotex PLC
("Cyprotex" or "the Company")
Director Shareholdings
Cyprotex PLC (AIM: CRX), the drug discovery, technology and information company today declares that, following the successful closing of its Placing and Open Offer at midday on Tuesday, 26th August, the Board of Directors holdings in the Company's enlarged capital (with percentage in parenthesis) is now as follows:
|
Mr Steve Harris |
Chairman |
800,000 (0.45%) |
|
Dr Anthony Baxter |
Chief Executive Officer |
600,000 (0.34%) |
|
Mr Russell Gibbs |
Chief Financial Officer |
1,240,000 (0.69%) |
|
Mr Nikolas Sofronis |
Non-Executive Director |
40,000 (0.02%) |
|
Mr David Evans |
Non-Executive Director |
25,000 (0.01%) |
These details can also be found on Cyprotex PLC's website, www.cyprotex.com , together with an up to date listing of Cyprotex PLC's major shareholders and their participations in accordance with AIM Rule 26.
For further information:
Cyprotex PLC Dr Anthony Baxter, CEO Tel: +44 (0)1625 505 100ir@cyprotex.comwww.cyprotex.com Russell Gibbs, CFO Tel: +44 (0)1625 505 100ir@cyprotex.comwww.cyprotex.com
Nomura Code Securities Limited Charles Walker, Giles Balleny Tel: +44 (0)20 7776 1200cew@nomuracode.comwww.nomuracode.com
Media EnquiresPelham PR Simon Miller Tel: +44 (0)20 3178 4419simon.miller@pelhampr.com
CRX.L (CRX)
Follow the stocks
